Dec. 13, 2013, 1:20 PM
- Ampio Pharmaceuticals (AMPE +3.3%) spins off its sexual dysfunction business into a standalone company called Vyrix Pharmaceuticals. The new entity will be funded through an IPO.
- Vyrix's assets will include Zertane and Zertane-ED, late stage drugs for which the new entity will initiate further trials and develop commercialization and marketing partnerships.
- The spin-off will be headed by Jarrett Disbrow, who was previously founder and CEO of Arbor Pharmaceuticals.
- Ampio expects the IPO to take up to 12 months and that the company will maintain a 50%-80% ownership in Vyrix.
AMPE vs. ETF Alternatives
Ampio Pharmaceuticals Inc is a biopharmaceutical company engaged in developing innovative, proprietary pharmaceutical drugs and diagnostic products to identify, treat and prevent human diseases including metabolic disorders, cancer etc.
Other News & PR